Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 5/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | PKLR | P30613 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12354637 | 0.84 | PKM (1.00) | PKMSMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL12346556 | 0.82 | PKM (0.61) | PKMSMN1; SMN2KMT2AMEN1POLB | |
| SCHEMBL30513335 | 0.80 | SMN1; SMN2 (0.79) | SMN1; SMN2KMT2AMEN1POLBKDM4E | |
| SCHEMBL12346544 | 0.79 | PKM (0.68) | PKMKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL28961516 | 0.75 | ALDH1A1 (0.66) | PKMPOLBKDM4EALDH1A1HTT | |
| SCHEMBL16587845 | 0.75 | ALDH1A1 (0.75) | SMN1; SMN2KMT2AMEN1POLBKDM4E | |
| SCHEMBL4040330 | 0.75 | KDM4E (0.75) | PKMSMN1; SMN2KMT2AMEN1POLB | |
| SCHEMBL23775577 | 0.74 | KDM4E (0.69) | PKMSMN1; SMN2KMT2AMEN1POLB | |
| SCHEMBL28919050 | 0.74 | HTT (0.54) | PKMKMT2APOLBALDH1A1HTT | |
| SCHEMBL14586771 | 0.73 | KDM4E (0.73) | SMN1; SMN2KMT2AMEN1POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9707230-B2 | Activators of human pyruvate kinase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-07-18 | — | — | US | disclosed |
| US-9403792-B2 | Methods of using pyruvate kinase activators | AGIOS PHARMACEUTICALS, INC (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160199370-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2016-07-14 | — | — | US | disclosed |
| US-9290512-B2 | Activators of human pyruvate kinase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150105395-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | US HEALTH (US) | 2015-04-16 | — | — | US | disclosed |
| US-8937067-B2 | Activators of human pyruvate kinase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-01-20 | — | — | US | disclosed |
| US-8841305-B2 | Activators of the human pyruvate kinase M2 receptor | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140148444-A1 | METHODS OF USING PYRUVATE KINASE ACTIVATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-05-29 | — | — | US | disclosed |
| US-20120245141-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2012-09-27 | — | — | US | disclosed |
| US-20110195958-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | US Dept. of Health and Human Services (US) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105395-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | PDK2, PDK1, PDK4 | PKM 4/4885SMN1; SMN2 2433/4885KMT2A 268/4885 |
| US-20140148444-A1 | METHODS OF USING PYRUVATE KINASE ACTIVATORS | PCK1, PDK2, PCK2 | PKM 14/4885SMN1; SMN2 2378/4885KMT2A 981/4885 |
| US-20110195958-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | PDK2, PDK1, PDK4 | PKM 5/4885SMN1; SMN2 2576/4885KMT2A 254/4885 |
| US-20160199370-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | PDK2, PDK1, PDK4 | PKM 4/4885SMN1; SMN2 2504/4885KMT2A 243/4885 |
| US-20120245141-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | PDK2, PDK1, PDK4 | PKM 4/4885SMN1; SMN2 2504/4885KMT2A 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.